Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children

Antiviral Therapy

Volumn 7, Issue 4, 2002, Pages 267-270

  King, Jennifer R ^a   Nachman, Sharon ^b   Yogev, Ram ^c   Hodge, Janice ^d   Aldrovandi, Grace ^a   Damle, Bharat ^e   Smith, Elizabeth ^f   Wiznia, Andrew ^g   Acosta, Edward P ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

^d FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g JACOBI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHELATION; CHEWABLE TABLET; CHILD; CHILD CARE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISPERSIBLE TABLET; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG TOLERABILITY; ENTERIC COATED TABLET; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SIDE EFFECT; TREATMENT OUTCOME;

ANTI-HIV AGENTS; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CHILD; CHILD, PRESCHOOL; DIDANOSINE; FEMALE; HIV INFECTIONS; HUMANS; MALE; TABLETS, ENTERIC-COATED;

EID: 0036977525     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Ahluwalia G, Cooney DA, Hartman NR, Mitsuya H, Yarchoan R, Fridland A, Broder S & Johns DG. Anomalous accumulation and decav of 2′,3′-dideoxyadenosine-5′-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2′,3′-dideoxyinosine. Drug Metabolism & Disposition 1993; 21:369-376.
2. Perry CM & Balfour JA. Didanosine: an update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease. Drugs 1996; 52:928-962.
3. St Clair MH, Pennington KN, Rooney J & Barry DW. In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the inter-company collaboration protocol. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1995; 10:s83-s91.
4. Sahai J, Gallicano K, Oliveras L, Khaliq S, Hawley-Foss N & Garber G. Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Clinical Pharmacology & Therapeutics 1993; 53:292-297.
5. Knupp CA, Brater DC & Relue J. Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. Journal of Clinical Pharmacology 1993; 33:912-917.
6. Acosta EP, Nachman S, Wiznia A, Turner M, Sommadossi J-P & Yogev R. Pharmacokinetic (PK) evaluation of nelfinavir (NFV) in combination with nevirapine (NVP) or ritonavir (RTV) in HIV-infected children - PACTG 403. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17-20, Toronto, ON, Canada, 2000. Abstract 1642.
7. Damle B, Yan J-H, Behr D, O'Mara E, Nichola P, Kaul S & Knupp C. Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads. Journal of Clinical Pharmacology 2002; 42:419-427.
8. Gibaldi M & Perrier D. Pharmacokinetics. 2nd edn 1982. New York, NY: Marcel Dekker.
9. Fletcher CV, Brundage RC, Remmel RP, Page LM, Weller D, Calles NR, Simon C & Kline MW. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. Antimicrobial Agents & Chemotherapy 2000; 44:1029-1034.
10. Stevens RC, Rodman JH, Yong FH, Carey V, Knupp CA, Frenkel LM & the Pediatric AIDS Clinical Trials Group Protocol 144 Team. Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. AIDS Research & Human Retroviruses 2000; 16:415-421.
11. Hoetelmans RMW, van Heeswijk RPG, Profijt M, Mulder JW, Meenhorst PL, Lange JMA, Reiss P & Beijnen JH. Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals. AIDS 1998; 12:F211-216.